Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA.

Nat Biomed Eng 2018 Dec;2(12):968

Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

The authors wish to add the following sentence into the 'Competing interests' section of this Article: "P.W.K. has investment interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences and Tarveda Therapeutics, is a company board member for Context Therapeutics LLC, is a consultant and scientific advisory board member for BIND Biosciences, Inc., BN Immunotherapeutics, DRGT, GE Healthcare, Janssen, Metamark, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics and Thermo Fisher, and serves on data safety monitoring boards for Genentech/Roche and Merck." This has now been included.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41551-018-0331-xDOI Listing
December 2018
5 Reads

Publication Analysis

Top Keywords

therapeutics llc
8
biosciences tarveda
8
seer biosciences
8
context therapeutics
8
tarveda therapeutics
8
board member
8
company board
4
therapeutics company
4
placon seer
4
therapeutics thermo
4
investment interest
4
"pwk investment
4
interest context
4
metamark england
4
member context
4
llc drgt
4
drgt placon
4
sanofi seer
4
institutes oncocellmdx
4
immunotherapeutics drgt
4

Similar Publications